Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis

Zhang, Jing; Zhang, Yueli; Ma, Kaixiang; Jian, Qu

doi:10.1136/thoraxjnl-2012-202592

Cited by 36 publications

(25 citation statements)

References 35 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The updated search identifi ed eight meta-analyses (1669-9861 patients) [103][104][105][106][107][108][109][110] and six randomised clinical trials [111][112][113][114][115][116] comparing anticoagulant prophylaxis with no intervention or placebo in ambulatory patients receiving systemic anticancer therapy. Overall, a signifi cant 45·0% reduction in VTE occurrence was reported across the six meta-analyses assessing the safety and effi cacy of LMWH compared with no intervention or placebo.…”

Section: Ambulatory Patients Treated With Systemic Anticancer Therapymentioning

confidence: 99%

“…and one meta-analysis 110 assessed VTE prophylaxis in patients with lung cancer. The TOPIC study included two double-blind trials comparing the LMWH certoparin (3000 IU per day) with placebo in ambulatory patients with metastatic breast cancer (TOPIC-1) or with stage III or IV non-small-cell lung carcinoma (NSCLC; TOPIC-2).…”

Section: Khorana Predictive Model For Chemotherapy-associated Vte 10mentioning

confidence: 99%

See 1 more Smart Citation

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

Farge

Bounameaux

Brenner

et al. 2016

The Lancet Oncology

388

434

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE and are more likely to have a recurrence of VTE and bleeding while taking anticoagulants. Management of VTE in patients with cancer is a major therapeutic challenge and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME), established to reduce the global burden of VTE in patients with cancer, published international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis. The rapid global adoption of direct oral anticoagulants for management of VTE in patients with cancer is an emerging treatment trend that needs to be addressed based on the current level of evidence. In this Review, we provide an update of the ITAC-CME consensus recommendations based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale. These guidelines aim to address in-hospital and outpatient cancer-associated VTE in specifi c subgroups of patients with cancer.

show abstract

Section: Ambulatory Patients Treated With Systemic Anticancer Therapymentioning

confidence: 99%

Section: Khorana Predictive Model For Chemotherapy-associated Vte 10mentioning

confidence: 99%

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

Farge

Bounameaux

Brenner

et al. 2016

The Lancet Oncology

388

434

View full text Add to dashboard Cite

show abstract

“…Moreover, anticoagulation with low molecular weight heparin (LMWH) was in several clinical studies associated with a detectable (albeit limited) survival advantage in certain cancer settings [20,[97][98][99][100][101][102].…”

Section: Coagulation System As Modulator Of Tumor Initiation Progresmentioning

confidence: 99%

Oncogenes and the coagulation system – forces that modulate dormant and aggressive states in cancer

Magnus

D’Asti

Meehan

et al. 2014

Thrombosis Research

View full text Add to dashboard Cite

“…Prophylactic thromboprophylaxis with LMWH is shown to significantly decrease the incidence of VTE in cancer patients being treated with chemotherapy. 13,14 Although it is …”

Section: Vte Prophylaxis In Ambulatory Cancer Patientsmentioning

confidence: 96%

Practical Approach to VTE Management in Hospitalized Patients

Reddy

Dupree

2017

American Journal of Therapeutics

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a commonly feared life-threatening complication in hospitalized patients. Physicians are frequently consulted to diagnose and manage VTE in obstetrics, neurology, and surgical services. VTE should be treated irrespective of the presentation (incidental or symptomatic), etiology (provoked vs. unprovoked), and location of the venous thrombosis (extremities, abdomen, or cerebral). In patients with high clinical suspicion for VTE, physicians are encouraged to empirically start anticoagulant therapy while awaiting diagnostic testing. Thrombolytic therapy is underused by physicians, which is proven to improve the mortality in hypotensive patients with pulmonary embolism. Retrievable inferior vena cava filters have an important role in the prophylaxis and management of selective groups of VTE patients. Physicians should not hesitate to place retrievable inferior vena cava filters when clinically indicated but also should make every effort to remove them when no longer needed. This article extensively reviews various diagnostic and management options based on several clinical situations.

show abstract

Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis

Cited by 36 publications

References 35 publications

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer

Oncogenes and the coagulation system – forces that modulate dormant and aggressive states in cancer

Practical Approach to VTE Management in Hospitalized Patients

Contact Info

Product

Resources

About